文献速递膀胱癌与上尿路尿路上皮癌

一项全地区研究:不同卡介苗菌株与剂量在中危及高危非肌层浸润性膀胱癌患者中的剂量与疗效

A Territory-wide Study Investigating the Dose and Efficacy of Different Bacillus Calmette-Guérin Strains in Patients with Intermediate- and High-risk Non-muscle-invasive Bladder Cancer.
PubMed 文献 · Eur Urol Oncol · 2023-10-11

该研究基于香港全地区数据库,纳入2001至2020年接受膀胱内卡介苗(BCG)治疗的2602例非肌层浸润性膀胱癌(NMIBC)患者,中位随访11.0年。多因素分析显示,Connaught 27 mg组在总生存(OS)、癌症特异性生存(CSS)和无进展生存(PFS)上劣于Connaught 81 mg组;充分BCG治疗与OS、CSS、无复发生存(RFS)和PFS改善相关。全剂量Connaught、Tokyo和Danish菌株间生存结局无显著差异。

要点

  • 充分BCG治疗是优化中高危NMIBC生存结局的最重要因素。
  • Connaught 27 mg组OS、CSS、PFS劣于Connaught 81 mg组。
  • 全剂量Connaught、Tokyo和Danish菌株间生存结局无显著差异。

核心结论

  • 充分BCG治疗仍是优化中危及高危NMIBC患者生存结局的最重要因素。
  • 全剂量Connaught、Tokyo和Danish菌株间未观察到生存结局的显著差异。
  • 减剂量Connaught菌株与最差的生存结局相关。

研究设计与样本

  • 利用香港全地区数据库识别2001至2020年接受膀胱内BCG治疗的所有NMIBC患者。
  • 共纳入2602例接受膀胱内BCG治疗的NMIBC患者。
  • BCG菌株与剂量从病历中获取:Connaught菌株81 mg、Connaught菌株27 mg、Tokyo菌株80 mg、Danish菌株30 mg。
  • 采用Kaplan-Meier法分析OS、CSS、RFS和PFS,多因素Cox回归调整潜在混杂因素并估计不同BCG菌株的HR和95%CI。
  • 进一步对充分与不充分BCG治疗进行亚组分析。

主要发现

  • 2602例中,1291例(49.6%)接受Connaught 81 mg,199例(7.6%)接受Connaught 27 mg,1014例(39.0%)接受Tokyo菌株,98例(3.8%)接受Danish菌株。
  • 中位随访11.0年,不同组间OS、CSS、RFS和PFS均未检测到统计学显著差异。
  • 多因素分析中,Connaught 27 mg组较Connaught 81 mg组OS更差(HR 1.26,95%CI 1.05-1.51)、CSS更差(HR 1.69,95%CI 1.08-2.66)、PFS更差(HR 1.86,95%CI 1.20-2.88)。
  • 充分BCG治疗与OS改善(HR 0.82,95%CI 0.73-0.92)、CSS改善(HR 0.64,95%CI 0.47-0.86)、RFS改善(HR 0.80,95%CI 0.70-0.92)和PFS改善(HR 0.52,95%CI 0.39-0.68)相关。
  • 在充分BCG治疗患者中,多因素分析显示Connaught 27 mg组较Connaught 81 mg组CSS更差(HR 1.93,95%CI 1.07-3.51)。

关键数值与推荐

  • 当前欧洲泌尿外科学会(EAU)指南支持中危或高危NMIBC患者在经尿道膀胱肿瘤电切术(TURB)后接受辅助膀胱内BCG治疗,以降低肿瘤复发风险。
  • 现有数据质量不足以就不同BCG菌株和剂量对长期生存结局的疗效差异做出确定性结论。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文指出数据质量不足以就不同BCG菌株和剂量对长期生存结局的疗效差异做出确定性结论。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Current European Association of Urology (EAU) guidelines support adjuvant intravesical Bacillus Calmette-Guérin (BCG) treatment after Transurethral Resection of Bladder Tumor (TURB) for intermediate- or high-risk Non-Muscle-Invasive Bladder Cancer (NMIBC) patients, aiming to reduce the risk of tumor recurrence. The quality of data, however, does not allow definitive conclusions on whether different strains and dosages of BCG have different efficacies on long-term survival outcomes. OBJECTIVE: To evaluate the long-term survival outcomes of different strains and dosages of BCG in patients with NMIBC. DESIGN, SETTING, AND PARTICIPANTS: All NMIBC patients treated with intravesical BCG therapy from 2001 to 2020 were identified using a territory-wide database in Hong Kong. INTERVENTION: BCG strains and dosages (Connaught strain 81 mg, Connaught strain 27 mg, Tokyo strain 80 mg, and Danish strain 30 mg) were retrieved from medical records. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Overall Survival (OS), Cancer-Specific Survival (CSS), Recurrence-Free Survival (RFS), and Progression-Free Survival (PFS) were analyzed using the Kaplan-Meier method. A multivariable Cox regression analysis was used to adjust potential confounding factors, and to estimate Hazard Ratio (HR) and 95% confidence interval (CI) of different BCG strains. A further subgroup analysis on adequate versus inadequate BCG treatment was performed. RESULTS AND LIMITATIONS: A total of 2602 NMIBC patients treated with intravesical BCG were identified. Among them, 1291 (49.6%) received Connaught strain 81 mg, 199 (7.6%) received Connaught strain 27 mg, 1014 (39.0%) received Tokyo strain, and 98 (3.8%) received Danish strain. The median follow-up was 11.0 years. No statistically significant differences in OS, CSS, RFS, and PFS were detected among the different groups. At the multivariable analysis, the Connaught strain 27 mg group was inferior to the Connaught strain 81 mg group in terms of OS (HR: 1.26, 95% CI: 1.05-1.51), CSS (HR: 1.69, 95% CI: 1.08-2.66), and PFS (HR: 1.86, 95% CI: 1.20-2.88). Adequate BCG treatment was associated with improved OS (HR: 0.82, 95% CI: 0.73-0.92), CSS (HR: 0.64, 95% CI: 0.47-0.86), RFS (HR: 0.80, 95% CI: 0.70-0.92), and PFS (HR: 0.52, 95% CI: 0.39-0.68). Among patients treated with adequate BCG, at the multivariable analysis the Connaught strain 27 mg group showed worse results than the Connaught strain 81 mg group in terms of CSS (HR: 1.93, 95% CI: 1.07-3.51). Compared with the Connaught strain 81 mg group, both Tokyo and Danish strains had similar survival outcomes in the whole cohort and the adequate BCG treatment subgroup. CONCLUSIONS: Our findings suggest that adequate BCG remains the most important factor in optimizing survival outcomes in patients with intermediate- and high-risk NMIBC. No significant differences in survival outcomes were observed between full-dose Connaught, Tokyo, and Danish strains. Reduced-dose Connaught strain was associated with the worst survival outcomes. PATIENT SUMMARY: We evaluated the efficacy of different strains and dosages of bacillus Calmette-Guérin (BCG) in patients with intermediate- or high-risk non-muscle-invasive bladder cancer in the past two decades in Hong Kong. We conclude no significant differences in long-term survival outcomes in terms of full-dose Connaught, Tokyo, and Danish strains, while reduced-dose Connaught strain was inferior to the full-dose group. Adequate BCG treatment benefits long-term survival.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Liu K, Zhao H, Chen X, et al. A Territory-wide Study Investigating the Dose and Efficacy of Different Bacillus Calmette-Guérin Strains in Patients with Intermediate- and High-risk Non-muscle-invasive Bladder Cancer. Eur Urol Oncol. 2023. PMID: 37827948. doi:10.1016/j.euo.2023.09.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。